NLRP3 and atrial fibrillation: Although pharmacologically targeting the NLRP3 inflammasome is still at an early stage, the causal relationship between inflammasome activation and AF identified in preclinical studies emphasizes the need for clinical research into the potential therapeutic benefits of NLRP3 inhibition in age-related AF.